62.2 F
New York
Friday, September 24, 2021

Dyadic International [NASDAQ: DYAI] Inks Licensing Agreement with the Rubic Consortium

Must read

XPeng [NYSE: XPEV] Backed HT Aero Launch Flying Vehicle City Usage Scenarios

XPeng Inc. disclosed that HT Aero has launched future urban usage scenarios for its fifth-generation flying vehicle XPeng X2 (X2). It includes independent...

Metrospaces Choose Cryptobucks as Preferred Cryptocurrency Partner

Metrospaces disclosed that it has selected Cryptobucks as its preferred cryptocurrency partner. It has inked an agreement to consolidate Cryptobucks into all of its...

Novartis [NYSE: NVS] Announces Acquisition of Arctos Medical

Novartis AG disclosed that it has acquired Arctos Medical. This purchase decision will add a pre-clinical optogenetics-based AAV gene therapy program and Arctos’...

Mastercard [NYSE: MA] Announces Launch of Sustainability Innovation Lab

Mastercard Incorporated has introduced a new sustainability innovation lab. The firm disclosed that its new lab will lead the further development of the...

Dyadic International, Inc. [NASDAQ: DYAI] disclosed that it has inked a COVID-19 vaccine technology transfer and licensing agreement with the Rubic Consortium. It has been disclosed by WHO that there are currently fewer than 10 African manufacturers. They have a vaccine production capacity based in 5 countries.

The strategic vision of Rubic is to establish a vaccine research hub and center for higher learning and R&D facilities. Its vision also includes the foundation of a vaccine manufacturing unit with the infrastructure, processing operations. It also includes capabilities for the manufacture and dissemination of high-quality vaccines throughout the African continent.

Furthermore, as per the agreement, Rubic licensed to use the C1 Platform for the research, development, regulatory support, manufacture, launch, marketing, and commercialization of a COVID-19 vaccine(s) that may be man-made in South Africa and sold in multiple countries on the African continent.

Moreover, it also includes that as per the deal Rubic will be accountable for awarding the projected design and funding of Phase II clinical trial within a particular timeframe of the completed technology transfer and licensing agreement.

More articles

Latest article

ReneSola [NYSE: SOL] and Eiffel’s Joint Venture Buys Its First 200 MW Project Portfolio

ReneSola Ltd disclosed that European Solar Energy Development JV has finalized the purchase of its first batch of solar projects with a combined...

Square [NYSE: SQ] Launch its Early Access Program in Spain

Square, Inc. which has earned a reputation as a software, payments, and hardware solution firm for all types of businesses disclosed that it...

Ideanomics [NASDAQ: IDEX] Decides to Increase Stake in Energica

Ideanomics, Inc. disclosed that it has decided to ink an agreement with Energica Company. As per the agreement, the firm has decided to...

L3Harris’ [NYSE: LHX] Robot Chosen to Protect US Air Force Bases Around the Globe

L3Harris Technologies, Inc. disclosed that it has received a huge contract from US Air Force. The firm revealed that its robot will now...

Tower Semiconductor [NASDAQ: TSEM] Introduces Breakthrough LiDAR Technology

Tower Semiconductor Ltd. has introduced a breakthrough development of LiDAR IC technology created for sophisticated driver-assistance systems (ADAS) and ultimately self-driving cars. The...

KKR [NYSE: KKR] Decides to Divest Riata Corporate Park

KKR & Co. Inc. has disclosed that it has decided to divest the Riata Corporate Park. Riata Corporate Park is an eight-building, 688,100...

3D Systems [NYSE: DDD] Unveil VisiJet Wax Jewel Red

3D Systems Corporation has launched the VisiJet Wax Jewel Red. It will allow jewelry makers to design and create more sophisticated, lasting patterns....

Xerox [NYSE: XRX] Announces Transfer of Stock Exchange Listing to Nasdaq from NYSE

Xerox Holdings Corporation has made an important announcement regarding its listing on Stock Exchange. The firm has revealed that it has decided to...